BRIEF published on 11/14/2024 at 19:05, 4 months 25 days ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 4 months 25 days ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 5 months 16 days ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 5 months 16 days ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 5 months 19 days ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 5 months 19 days ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 7 months 18 days ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 7 months 18 days ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 9 months 8 days ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 9 months 8 days ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
Published on 04/09/2025 at 20:10, 22 minutes ago Taranis Quantifies Hydrothermal Alteration System at Thor to Improve Targeting for 2025 Deep Exploration Drilling
Published on 04/09/2025 at 18:00, 2 hours 32 minutes ago BrooQLy Inc. (BRQL) dba Dynamic Aerospace Systems Appoints FedEx Leader in Logistics to Board of Directors
Published on 04/09/2025 at 15:15, 5 hours 17 minutes ago Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 04/09/2025 at 15:00, 5 hours 32 minutes ago The Cree Trappers Association, the Cree Hunters Economic Security Board and Mining & Exploration Companies Approve 2025 Funding to Continue the Reconstruction of Cabins Burnt During the 2023 Forest Fires, James Bay, Quebec
Published on 04/09/2025 at 15:00, 5 hours 32 minutes ago The Cree Trappers Association, the Cree Hunters Economic Security Board and Mining & Exploration Companies Approve 2025 Funding to Continue the Reconstruction of Cabins Burnt during the 2023 Forest Fires, James Bay, Quebec
Published on 04/09/2025 at 20:20, 11 minutes ago Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences
Published on 04/09/2025 at 20:18, 14 minutes ago EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG publishes preliminary key figures for the financial statements as of March 31, 2025
Published on 04/09/2025 at 19:08, 1 hour 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/09/2025 at 18:34, 1 hour 57 minutes ago PolyPeptide announces results of the annual General Meeting 2025
Published on 04/09/2025 at 18:02, 2 hours 29 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/09/2025 at 18:59, 1 hour 32 minutes ago Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:57, 1 hour 34 minutes ago Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 17:45, 2 hours 47 minutes ago COGELEC : 2024 full-year results and Q1 2025 revenue.
Published on 04/09/2025 at 17:40, 2 hours 52 minutes ago COGELEC : Statement on the total number of shares and voting rights.
Published on 04/09/2025 at 08:00, 12 hours 32 minutes ago Museum Studio becomes a majority shareholder in Lord Cultural Resources
